| Title: | APOEε4 carriage associates with improved myocardial performance from adolescence to older age |
| Journal: | BMC Cardiovascular Disorders |
| Published: | 21 Mar 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38509472/ |
| DOI: | https://doi.org/10.1186/s12872-024-03808-z |
| URL: | https://bmccardiovascdisord.biomedcentral.com/counter/pdf/10.1186/s12872-024-03808-z |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 10071
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundAlthough APOE ε4 allele carriage confers a risk for coronary artery disease, its persistence in humans might be explained by certain survival advantages (antagonistic pleiotropy).MethodsCombining data from ~ 37,000 persons from three older age British cohorts (1946 National Survey of Health and Development [NSHD], Southall and Brent Revised [SABRE], and UK Biobank) and one younger age cohort (Avon Longitudinal Study of Parents and Children [ALSPAC]), we explored whether APOE ε4 carriage associates with beneficial or unfavorable left ventricular (LV) structural and functional metrics by echocardiography and cardiovascular magnetic resonance (CMR).ResultsCompared to the non-APOE ε4 group, APOE ε4 carriers had similar cardiac phenotypes in terms of LV ejection fraction, E/e', posterior wall and interventricular septal thickness, and LV mass. However, they had improved myocardial performance resulting in greater LV stroke volume generation per 1 mL of myocardium (higher myocardial contraction fraction). In NSHD (n = 1467) and SABRE (n = 1187), ε4 carriers had a 4% higher MCF (95% CI 1-7%, p = 0.016) using echocardiography. Using CMR data, in UK Biobank (n = 32,972), ε4 carriers had a 1% higher MCF 95% (CI 0-1%, p = 0.020) with a dose-response relationship based on the number of ε4 alleles. In addition, UK Biobank ε4 carriers also had more favorable radial and longitudinal strain rates compared to non APOE ε4 carriers. In ALSPAC (n = 1397), APOE ε4 carriers aged < 24 years had a 2% higher MCF (95% CI 0-5%, p = 0.059).ConclusionsBy triangulating results in four independent cohorts, across imaging modalities (echocardiography and CMR), and in ~ 37,000 individuals, our results point towards an association between ε4 carriage and improved cardiac performance in terms of LV MCF. This potentially favorable cardiac phenotype adds to the growing number of reported survival advantages attributed to the pleiotropic effects APOE ε4 carriage that might collectively explain its persistence in human populations.</p>
13 Authors
- Constantin-Cristian Topriceanu
- Mit Shah
- Matthew Webber
- Fiona Chan
- Hunain Shiwani
- Marcus Richards
- Jonathan Schott
- Nishi Chaturvedi
- James C. Moon
- Alun D. Hughes
- Aroon D. Hingorani
- Declan P. O'Regan
- Gabriella Captur
Enabling scientific discoveries that improve human health